Rheumatology Journals
Rheumatology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?


Article ID

Home
General Rheumatology
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
Rheumatology
        Amyloidosis
        Autoimmune/Heritable
        Basic Science/Genetics
        Bone Metabolism
        Chr Fatigue/Fibromyalgia
        Clinical Pharmacology
        Connective Tissue Dz
        Diagnostics/Radiology
        Economics of Medicine
        Gout and Hyperuricemia
        Infectious Arthritis
        Osteoarthritis
        Other Arthritis
        Pediatric Rheumatology
        Popular Press
        Rheumatoid Arthritis
        Spondylarthropathies
        Systemic Lupus (SLE)
        Vasculitic Syndromes
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
Top Ten Searches
rheumatoid arthritis  rheumatoid arthritis
lupus  lupus
polymyalgia  polymyalgia
sjogrens  sjogrens
fibromyalgia  fibromyalgia
amyloidosis  amyloidosis
vasculitis  vasculitis
urate  urate
raynauds  raynauds
myositis  myositis
 
Sponsor
MDLinx Email Article

To email this article, enter your own "From Email" address,
the recipient's "To Email" address, and click the "Send Email" button.
You may send to up to 5 email addresses.
*From Email:  
*To Email:  
To Email:  
To Email:  
To Email:  
To Email:  
Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs
Noh JY et al. – Study reports that the time of onset of MPO-ANCA-associated vasculitis and the dose at onset varied. The severity and number of organs involved were not correlated with the MPO-ANCA titre, warranting the need for vigilance even when the titre is weakly positive.

Methods
  • An analysis of pts with MPO-ANCA-associated vasculitis to determine:
    • Time of onset
    • Drug and dose taken
    • Clinical symptoms
    • Relationship between the clinical symptoms and the MPO-ANCA titre, and the incidence
  • 92 pts in whom the adverse reaction of MPO-ANCA-associated vasculitis was reported were analysed

Results
  • Organ failure reported as:
    • 41/92 (44.6%) pts had single-organ failure
    • 34.8% had two-organ failure
    • 14.1% had three-organ failure
    • 2.2% had four-organ failure
    • Number of organs involved was unknown in 4.3% of pts
  • Median time of onset was 42 mo after starting drug treatment
  • Median dose at onset of MPO-ANCA-associated vasculitis was 15 mg/d for methimazole, and 200 mg/d for propylthiouracil
  • Severity and number of organs involved were not correlated with the MPO-ANCA titre
  • Incidence was between 0.53 and 0.79 pts per 10,000
  • Ratio of the estimated incidences for methimazole and propylthiouracil was 1:39.2
[more...]
Sponsor

Read a Different Specialty

General Rheumatology Articles
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Profession Index

General Rheumatology Articles
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2009 MDLinx, Inc.